“This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer’s instead of only treating the symptoms of the disease,” FDA neuroscience official Billy Dunn said in a statement.

Source: https://financialpost.com/pmn/business-pmn/eisai-biogen-get-u-s-fda-approval-for-alzheimers-drug-apply-for-full-approval